U.S. Administrative Headquarters
Morris Corporate Center III, 400 Interpace Parkway
Tel: 1 (862) 261-7000
About Allergan, Inc.
Allergan plc (AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world.
Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry.
We’re Looking for the World’s Best
At Allergan, we are committed to recruiting and retaining the industry’s best and brightest employees and are proud to offer opportunities for military veterans at all levels across our company. We offer business, scientific, technical, engineering, sales & marketing and a variety of other positions here in the U.S. and around the world.
At Allergan, you will find an entrepreneurial style work environment where employees and employee teams are encouraged to apply their unique talents to grow, contribute, innovate and excel. We welcome your ideas. We provide the support, resources and encouragement that enable you to take your career to new heights. We focus on challenging you, challenging ourselves and driving success.
Commit to your future and join us. Learn more about our exciting career opportunities at www.allergan.com/careers.
Founder: Gavin S. Herbert
CEO: Brenton L. Saunders
CFO: Maria Teresa Hilado
Please click here for clinical trial information.
1187 articles about Allergan, Inc.
Allergan Reports Fourth Quarter and Full-Year 2019 Financial Results
Allergan plc reported its full-year and fourth quarter 2019 financial results including full-year 2019 GAAP net revenues of $16.1 billion, a 1.9 percent increase from 2018.
Allergan to Report Fourth Quarter and Full Year 2019 Financial Results
Allergan plc (NYSE: AGN) today announced it will release fourth quarter and full year 2019 financial results on Monday, February 10, 2020, prior to the open of U.S. financial markets.
Histogen and Allergan Expand Cell Conditioned Media (CCM) Skin Care Partnership
Histogen Inc., a regenerative medicine company with a unique biological platform that replaces and regenerates tissues in the body, today announced it has expanded its partnership with leading global biopharmaceutical company, Allergan.
All three companies have invested millions in the facilities to expand their global footprint.
AbbVie Announces Extension of Expiration Date for Exchange Offers for Allergan Notes to February 28, 2020
AbbVie Inc. announced the extension of the expiration date of the offers to exchange any and all outstanding notes of certain series issued by Allergan Finance, LLC, Allergan, Inc., Allergan Sales, LLC and Allergan Funding SCS for new notes to be issued by AbbVie and the related consent solicitations being made by AbbVie on behalf of Allergan to adopt certain amendments to each of the indentures governing the Allergan Notes.
AbbVie and Allergan Announce Agreements to Divest Brazikumab and Zenpep
Agreements Contingent on FTC and European Commission Approval and Completion of AbbVie's Pending Acquisition of Allergan
As AbbVie and Allergan near completion of the $63 billion merger, the two companies are shedding some assets in order to meet demands of regulators over concerns of a monopoly.
Allergan Declares First Quarter 2020 Cash Dividend of $0.74 Per Ordinary Share
Allergan plc (NYSE: AGN) today announced that its Board of Directors has declared a cash dividend of $0.74 per ordinary share for the first quarter of 2020
SkinMedica® Launches New Instant Bright Eye Cream For Immediate, Visible Results
Allergan plc (NYSE: AGN) announced today the launch of the SkinMedica® Instant Bright Eye Cream, a refreshing eye treatment that hydrates, brightens and helps visibly firm the appearance of the delicate skin around the eyes.
Allergan Teams Up With Super Bowl MVP Von Miller to Raise Awareness of Glaucoma's Impact on Daily Living
Allergan plc (NYSE: AGN), a leading global pharmaceutical company with more than 70 years of heritage in eye care, announced today a partnership with Von Miller, Super Bowl MVP, Denver Broncos linebacker and advocate for healthy vision, to shine a light on the millions of people living with glaucoma
Consulting firm EY released its annual report on mergers and acquisitions (M&A) to coincide with the JP Morgan Healthcare conference this week. For 2019, EY indicates there were $357 billion in life science deals, an “all-time record,” surpassing the previous high in 2014.
Top Biopharma M&As in 2019
1/10/2020The year was marked by mergers and acquisitions both big and small. Although not comprehensive, here’s a look at some of the top deals for 2019.
While Allergan and AbbVie prepare to complete their $63 billion merger later this year, plans are being laid out for a new, stand-alone company called Allergan Aesthetics that will include Botox as a tent pole.
Although much of the recent attention to CRISPR gene editing has been negative, CRISPR still remains one of the great hopes for treating diseases.
Ironwood and Allergan Announce Settlement Resolving LINZESS® (linaclotide) Patent Litigation
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today that the companies have reached an agreement with Sandoz Inc. (Sandoz) resolving patent litigation brought in response to Sandoz’s abbreviated new drug application (ANDA) seeking approval to market generic versions of LINZESS (linaclotide) prior to the expiration of the companies’ applicable patents.
Warner Chilcott and Watson Resolve Antitrust Class Action Litigation with Direct and Indirect Purchasers of Loestrin 24 Fe and Minastrin 24 Fe
Allergan plc, announced that its Warner Chilcott and Watson subsidiaries have reached resolutions with all plaintiffs, including a class of direct purchasers, individual direct purchasers that previously opted out of the direct purchaser class, and a class of indirect purchasers of Loestrin 24 Fe and Minastrin 24 Fe, concluding the previously disclosed antitrust litigation in the U.S. District Court for the District of Rhode Island.
BTL Files Patent Infringement Lawsuit Against Allergan and Zimmer Related to Emsculpt
BTL Aesthetics ("BTL"), a leading manufacturer of non-invasive technologies for body shaping, announced today that its U.S. affiliate has filed a lawsuit against Allergan plc, Ireland and its affiliates, and Zimmer MedizinSysteme GmbH, Germany, and its affiliate, in the U.S. Federal District Court for the District of Delaware.
The 12 Days of Christmas, Biopharma Style
12/25/2019To help kick off the holiday season, BioSpace gave this Christmas classic a unique biopharma spin.
Allergan Receives U.S. FDA Approval for UBRELVY™ for the Acute Treatment of Migraine with or without Aura in Adults
UBRELVY™ is the first and only oral CGRP receptor antagonist (gepant) FDA-approved for the acute treatment of migraine
Amgen And Allergan Submit Biologics License Application For ABP 798, Biosimilar Candidate To Rituxan® (rituximab), To U.S. Food And Drug Administration
Filing for ABP 798 Supported by Two Comparative Clinical Studies